|Table of Contents|

Advances in molecular markers to predict the risk of postoperative high-risk recurrence of stage Ⅰ non-small cell lung cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 14
Page:
2723-2726
Research Field:
Publishing date:

Info

Title:
Advances in molecular markers to predict the risk of postoperative high-risk recurrence of stage Ⅰ non-small cell lung cancer
Author(s):
WANG Zhihui1; DENG Hongbin2; DENG Lili1
1.The Second Affiliated Hospital of Harbin Medical University,Heilongjiang Harbin 150086,China;2.The First Affiliated Hospital of Harbin Medical University,Heilongjiang Harbin 150001,China.
Keywords:
non-small cell lung cancer; postoperative recurrence; prognosis; molecular markers
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2023.14.030
Abstract:
Surgical resection is the first choice for stage I non-small cell lung cancer (NSCLC) while the vast majority of patients still die from postoperative tumor recurrence.In recent years,the development of molecular markers represented by gene-related prognostic markers such as gene expression profiles and DNA methylation.Circulating prognostic markers such as circulating tumor cells(CTCs)，circulating cell-free nucleic acids［circulating tumor DNA(ctDNA) and microRNA(miRNA)］，immune-related prognostic factors such as programmed death-ligand 1（PD-L1） and tumor mutational burden（TMB） provide a new direction for predicting the risk of recurrence after stage I NSCLC.This article reviews the research progress of molecular markers related to the high-risk recurrence risk of stage I non-small cell lung cancer after surgery,and summarizes the significance of these molecular markers in determining the postoperative high-risk recurrence risk of stage I NSCLC.

References:

［1］GOLDSTRAW P,CHANSKY K,CROWLEY J,et al.The IASLC lung cancer staging project:Proposals for revision of the TNM stage groupings in the forthcoming(eighth) edition of the TNM classification for lung cancer［J］.J Thorac Oncol,2016,11(1):39-51.
［2］PARK HL,YOO IR,BOO SH,et al.Does FDG PET/CT have a role in determining adjuvant chemotherapy in surgical margin-negative stage IA non-small cell lung cancer patients［J］.Journal of Cancer Research and Clinical Oncology,2019,145(4):1021-1026.
［3］ZHANG M,ZHU K,PU H,et al.An immune-related signature predicts survival in patients with lung adenocarcinoma［J］.Frontiers in Oncology,2019,9:1314.
［4］KRATZ JR,HE J,VAN DEN EEDEN SK,et al.A practical molecular assay to predict survival in resected non-squamous,non-small-cell lung cancer:development and international validation studies［J］.Lancet(London,England),2012,379(9818):823-832.
［5］CHEN EG,WANG P,LOU H,et al.A robust gene expression-based prognostic risk score predicts overall survival of lung adenocarcinoma patients［J］.Oncotarget,2018,9(6):6862-6871.
［6］YAN Y,ZHANG M,XU S,et al.Identification of an immune gene expression signature for predicting lung squamous cell carcinoma prognosis［J］.BioMed Research International,2020,2020:5024942.
［7］TANG X,QI C,ZHOU H,et al.A novel metabolic-immune related signature predicts prognosis and immunotherapy response in lung adenocarcinoma［J］.Heliyon,2022,8(8):e10164.
［8］CUI Y,WANG X,ZHANG L,et al.A novel epithelial-mesenchymal transition(EMT)-related gene signature of predictive value for the survival outcomes in lung adenocarcinoma［J］.Frontiers in Oncology,2022,12:974614.
［9］CHO WCS,TAN KT,MA VWS,et al.Targeted next-generation sequencing reveals recurrence-associated genomic alterations in early-stage non-small cell lung cancer［J］.Oncotarget,2018,9(91):36344-36357.
［10］ZHANG J,LUO L,DONG J,et al.A prognostic 11-DNA methylation signature for lung squamous cell carcinoma［J］.Journal of Thoracic Disease,2020,12(5):2569-2582.
［11］WANG X,ZHOU B,XIA Y,et al.A methylation-based nomogram for predicting survival in patients with lung adenocarcinoma［J］.BMC Cancer,2021,21(1):801.
［12］WANG H,WEI C,PAN P,et al.Identification of a methylomics-associated nomogram for predicting overall survival of stage Ⅰ-Ⅱ lung adenocarcinoma［J］.Scientific Reports,2021,11(1):9938.
［13］MA X,CHENG J,ZHAO P,et al.DNA methylation profiling to predict recurrence risk in stage Ⅰ lung adenocarcinoma:Development and validation of a nomogram to clinical management［J］.Journal of Cellular and Molecular Medicine,2020,24(13):7576-7589.
［14］BELINSKY SA,LENG S,WU G,et al.Gene methylation biomarkers in sputum and plasma as predictors for lung cancer recurrence［J］.Cancer Prevention Research(Philadelphia),2017,10(11):635-640.
［15］SANDOVAL J,MENDEZ-GONZALEZ J,NADAL E,et al.A prognostic DNA methylation signature for stage Ⅰ non-small-cell lung cancer［J］.Journal of Clinical Oncology,2013,31(32):4140-4147.
［16］YANG L,ZHANG J,YANG G,et al.The prognostic value of a methylome-based malignancy density scoring system to predict recurrence risk in early-stage lung adenocarcinoma［J］.Theranostics,2020,10(17):7635-7644.
［17］WU Y,JING H,ZHANG J.MicroRNA-340 and microRNA-450b-5p:Plasma biomarkers for detection of non-small-cell lung cancer［J］.Journal of Environmental and Public Health,2022,2022:8024700.
［18］LI S,LIN Y,WU Y,et al.The value of serum exosomal miR-184 in the diagnosis of NSCLC［J］.Journal of Healthcare Engineering,2022,2022:9713218.
［19］KANAOKA R,IINUMA H,DEJIMA H,et al.Usefulness of plasma exosomal microRNA-451a as a noninvasive biomarker for early prediction of recurrence and prognosis of non-small cell lung cancer［J］.Oncology,2018,94(5):311-323.
［20］DEJIMA H,IINUMA H,KANAOKA R,et al.Exosomal microRNA in plasma as a non-invasive biomarker for the recurrence of non-small cell lung cancer［J］.Oncology Letters,2017,13(3):1256-1263.
［21］SUN L,ZHOU H,YANG Y,et al.Meta-analysis of diagnostic and prognostic value of miR-126 in non-small cell lung cancer［J］.Bioscience Reports,2020,40(5):BSR20200349.
［22］PENG M,HUANG Q,YIN W,et al.Circulating tumor DNA as a prognostic biomarker in localized non-small cell lung cancer［J］.Frontiers in Oncology,2020,10:561598.
［23］ZHANG R,ZHANG X,HUANG Z,et al.Development and validation of a preoperative noninvasive predictive model based on circular tumor DNA for lymph node metastasis in resectable non-small cell lung cancer［J］.Translational Lung Cancer Research,2020,9(3):722-730.
［24］LI N,WANG BX,LI J,et al.Perioperative circulating tumor DNA as a potential prognostic marker for operable stage Ⅰ to ⅢA non-small cell lung cancer［J］.Cancer,2022,128(4):708-718.
［25］GALE D,HEIDER K,RUIZ-VALDEPENAS A,et al.Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer［J］.Annals of Oncology,2022,33(5):500-510.
［26］WANKHEDE D,GROVER S,HOFMAN P.Circulating tumor cells as a predictive biomarker in resectable lung cancer:A systematic review and Meta-analysis［J］.Cancers,2022,14(6112):14.
［27］KAPELERIS J,EBRAHIMI WARKIANI M,KULASINGHE A,et al.Clinical applications of circulating tumour cells and circulating tumour DNA in non-small cell lung cancer-An update［J］.Frontiers in Oncology,2022,12:859152.
［28］DONG J,ZHU D,TANG X,et al.Detection of circulating tumor cell molecular subtype in pulmonary vein predicting prognosis of stage Ⅰ-Ⅲ non-small cell lung cancer patients［J］.Frontiers in Oncology,2019,9:1139.
［29］DONG J,ZHU D,TANG X,et al.Circulating tumor cells in pulmonary vein and peripheral arterial provide a metric for PD-L1 diagnosis and prognosis of patients with non-small cell lung cancer［J］.PLoS One,2019,14(7):e0220306.
［30］HE Y,SHI J,SCHMIDT B,et al.Circulating tumor cells as a biomarker to assist molecular diagnosis for early stage non-small cell lung cancer［J］.Cancer Management and Research,2020,12:841-854.
［31］AZUMA K,OTA K,KAWAHARA A,et al.Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer［J］.Annals of Oncology,2014,25(10):1935-1940.
［32］D'LNCECCO A,ANDREOZZI M,LUDOVINI V,et al.PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients［J］.British Journal of Cancer,2015,112(1):95-102.
［33］COOPER WA,TRAN T,VILAIN RE,et al.PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma［J］.Lung Cancer(Amsterdam,Netherlands),2015,89(2):181-188.
［34］YANG CY,LIN MW,CHANG YL,et al.Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage Ⅰ pulmonary squamous cell carcinoma［J］.European Journal of Cancer(Oxford,England：1990),2016,57:91-103.
［35］ZHANG B,LIU Y,ZHOU S,et al.Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatment for non-small cell lung cancer:A Meta-analysis［J］.International Immunopharmacology,2020,80:106214.
［36］ARAK H,AYTEKIN A,CANOZ O,et al.Prognostic and predictive significance of PD-L1 expression in non-small cell lung cancer patients:A single-center experience［J］.Turk Patoloji Dergisi,2021,37(3):239-248.
［37］SALEH RR,SCOTT JL,METI N,et al.Prognostic value of programmed death ligand-1 expression in solid tumors irrespective of immunotherapy exposure:A systematic review and Meta-analysis［J］.Molecular Diagnosis & Therapy,2022,26(2):153-168.
［38］梁文华.基于分子标志的非小细胞肺癌术后复发预测专家共识［J］.中华肺癌杂志，2022,25(10):701-714. LIANG WH.Consensus on postoperative recurrence prediction of non-small cell lung cancer based on molecular markers［J］.Chinese Journal of Lung Cancer,2022,25(10):701-714.
［39］TALVITIE EM,VILHONEN H,KURKI S,et al.High tumor mutation burden predicts favorable outcome among patients with aggressive histological subtypes of lung adenocarcinoma:A population-based single-institution study［J］.Neoplasia(New York),2020,22(9):333-342.
［40］WANG C,LIANG H,LIN C,et al.Molecular subtyping and prognostic assessment based on tumor mutation burden in patients with lung adenocarcinomas［J］.International Journal of Molecular Sciences,2019,20(17):4251.
［41］KRATZ JR,LI JZ,TSUI J,et al.Genetic and immunologic features of recurrent stage I lung adenocarcinoma［J］.Scientific Reports,2021,11(1):23690.
［42］GU W,WANG N,GU W,et al.Molecular gene mutation profiles,TMB and the impact of prognosis in Caucasians and east Asian patients with lung adenocarcinoma［J］.Translational Lung Cancer Research,2020,9(3):629-638.

Memo

Memo:
-
Last Update: 1900-01-01